News
Eli Lilly’s blockbuster diabetes drug Mounjaro matched the ability of an older treatment to prevent major heart complications ...
Eli Lilly's Mounjaro matched Trulicity in heart outcomes and showed added benefits on A1C, weight, kidney function, and ...
Eli Lilly & Co.’s blockbuster diabetes drug Mounjaro was about as good at preventing heart attacks and strokes as its older ...
A variety of GLP-1 drugs that were developed to treat Type 2 diabetes, including Novo Nordisk’s Ozempic, have secured label ...
Eli Lilly's diabetes drug Mounjaro demonstrated superior efficacy to its predecessor Trulicity in reducing heart attack and ...
The fast-selling GLP-1 drug matched Lilly's older medicine Trulicity in a closely watched cardiovascular outcomes trial, while showing greater weight loss and blood sugar control.
"The Mounjaro (tirzepatide) Patient Information Leaflet warns that hair loss is a common side effect in patients treated with ...
Eli Lilly's Mounjaro diabetes drug has demonstrated superior performance over Trulicity in reducing heart attack and stroke ...
A YOUNG woman has revealed that in 14 weeks, she has lost three stone on Mounjaro. But although Jess now feels “healthier” ...
Eli Lilly drug Mounjaro resulted in a lower risk of heart attacks and strokes in patients with diabetes compared with the ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback